Draft:Glooko
Submission declined on 9 April 2026 by Heavy Grasshopper (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Submission declined on 27 March 2026 by Moritoriko (talk). This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that:
Declined by Moritoriko 6 months ago.
| |
Comment: Only source added since last review is a regulatory document that does not speak to notability. Please add independent sources; press releases are not sufficient and routine funding updates don't help either. Please see WP:NOTABILITY. Heavy Grasshopper (talk) 15:08, 9 April 2026 (UTC)
Glooko
[edit]Glooko, Inc. is a privately held global digital health company headquartered in Palo Alto, California, that provides a unified, connected care platform for diabetes management[1]. The platform's core offering is a system that allows people with diabetes and their healthcare providers to collect, view, analyze, and act upon diabetes data from a wide variety of diabetes and health monitoring devices and applications offered by company partners, including Novo Nordisk, Insulet, Abott, and Dexcom.
History and Development
[edit]Glooko was founded in 2010 in Silicon Valley by venture capitalist Yogen Dalal, Chamath Palihapitiya and mobile developer Sundeep Madra. Dalal conceived the idea as a way to collect and visualize his own blood glucose data, addressing the fragmentation caused by siloed data from diabetes devices[2]. The first product was the Glooko MeterSync Cable, an FDA-cleared solution that enabled the transfer of data from various blood glucose meters to a smartphone[3]. The company also offered an insulin dosing calculator for Type 2 Diabetes, approved by the FDA, through its platform. The company has secured investments, including a reported $100 million Series F funding round in October 2024, led by Georgian.[4]
Glooko has used acquisitions to expand its diabetes management platform capabilities and market reach.
- Diasend (September 2016): Merged to expand Glooko's global presence (especially Europe) and increase overall device compatibility.[5]
- xbird (January 2022): Acquired Berlin-based health AI company to enhance personalized digital coaching through machine learning and JITAI (Just In Time Adaptive Intervention).[6]
- DIABNEXT (March 2022): Acquired to support local remote monitoring programs in France.[7] Product is now offered as Glooko XT in the French market.
- Monarch Medical Technologies (September 2025): Acquired the maker of the EndoTool® Glucose Management System, an FDA-cleared software for optimizing insulin dosing in hospitalized patients.[8]
External links
[edit]References
[edit]- ↑ "Diabetes Apps & Digital Therapeutics l Glooko". ADCES. Retrieved 2025-11-07.
- ↑ Parmar, Arundhati (2018-05-28). "New Glooko CEO: Livongo gets a lot of press but our approach is different". MedCity News. Retrieved 2025-11-07.
- ↑ FinSMEs (2014-01-08). "Glooko Raises $7M in Series A-1 Funding". FinSMEs. Retrieved 2025-11-07.
- ↑ "Glooko scores $100M and appoints new CEO | MobiHealthNews". www.mobihealthnews.com. 2024-10-11. Retrieved 2026-03-26.
- ↑ louisakewell (2016-09-16). "Glooko and Diasend Merge to Deliver the World's Premier Diabetes Management Platform". European Medical Journal. Retrieved 2026-03-26.
- ↑ Ford, Omar (2022-01-31). "Glooko Keeps Diabetes Management Space Hot with M&A". www.mddionline.com. Retrieved 2025-11-07.
- ↑ Pennic, Fred (2022-03-16). "Glooko Acquires DIABNEXT to Expand Diabetes Offerings in France". Retrieved 2025-11-07.
- ↑ Gormley, Brian (2025-09-25). "Consolidation Surge Hits Healthtech". Wall Street Journal. ISSN 0099-9660. Retrieved 2026-03-26.
- provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.